Resources
Filter by Topic
- Blogs
By Samy Suissa, PhD, Distinguished James McGill Professor of Epidemiology, Biostatistics, and Medicine, McGill University
- Press Releases
Panalgo, a Norstella company dedicated to revolutionizing healthcare data analytics, is announcing a new venture with partner OM1, a forefront leader in real-world evidence (RWE)...
- Press Releases
Norstella, one of the largest global pharma intelligence solution providers, today announced a strategic partnership with Atropos Health, the pioneer in translating real-world clinical data...
- Blogs
By Peter Neumann Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center;...
- Blogs
By Meg Richards, PhD, MPH, Executive Director of Solutions, Panalgo
- Articles
By Meg Richards, PhD, MPH, Executive Director, Scientific Strategy at Panalgo, with Andrew Goldstein, VP of Client Partnerships at Panalgo
- Blogs
Three Key Themes from Panalgo’s Data to Insights 2024 Conference
Faster Evidence, Fewer Bottlenecks: How IHD Is Redefining What’s Possible in Evidence Generation
As the demands on real-world data teams continue to grow, with more data sources, more stakeholders, and more pressure to deliver trusted evidence faster, the tools supporting that work need to evolve just as quickly.
Accelerating HEOR and Real-World Evidence: How IHD Helps Researchers Turn Evidence Into Impact
Health economics and outcomes research (HEOR), epidemiology, and real-world evidence (RWE) teams are under growing pressure to deliver meaningful insights faster than ever before. As healthcare stakeholders demand stronger evidence of clinical, economic, and humanistic value across the product life cycle, researchers need more than data—they need the right combination of technology, expertise, and fit-for-purpose evidence sources to turn research into impact.
How Pharma Leaders Are Rethinking Evidence Generation in the AI Era
Learn what organizations must do to balance speed, transparency, governance, and innovation in an increasingly data-driven and AI-reliant environment.
Where Treatment Slows in Metastatic NSCLC: A Real-World Data Analysis of Care Delays and Access Barriers
As regulators around the world grow more comfortable with real-world data (RWD) and AI-enabled evidence generation, pharma companies are rethinking how, and when, they build evidence.
Pharma’s New Regulatory Reality: Building Evidence for Launch and Beyond
As regulators around the world grow more comfortable with real-world data (RWD) and AI-enabled evidence generation, pharma companies are rethinking how, and when, they build evidence.
Smarter Data, Better Outcomes: How Real-World Data Is Transforming Evidence Generation Across the Product Lifecycle
As real-world data (RWD) becomes more central to healthcare decision making, evidence generation is playing an increasingly important role, from early identification to treatment optimization
IHD Analytics
Put reliable, rapid analytics in the hands of more people across your organization